Enterprise Value

59.11M

Cash

84.39M

Avg Qtr Burn

-18.66M

Short % of Float

0.88%

Insider Ownership

12.13%

Institutional Own.

28.42%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
UCART22 Details
Acute lymphoblastic leukemia, Rare genetic disease, Cancer, B-cell acute lymphoblastic leukemia

Phase 1/2

Data readout

UCART20x22 Details
Cancer, Non-Hodgkin lymphoma

Phase 1/2

Data readout

UCART123 Details
Cancer, Relapsed/refractory acute myeloid leukemia

Phase 1

Data readout

ALLO-501 Details
Non-Hodgkin lymphoma, Cancer

Failed

Discontinued

ALLO-715 Details
Cancer, Multiple myeloma

Failed

Discontinued

UCARTCS1 Details
Cancer, Multiple myeloma, Menkes Disease

Failed

Discontinued

UCART19 (anti-CD19) Details
Cancer, Multiple myeloma, Acute lymphoblastic leukemia

Failed

Discontinued